Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Adding acalabrutinib to the arsenal: impact of ASCEND in CLL

Barbara Eichhorst, MD, University Hospital of Cologne, Cologne, Germany, discusses the ASCEND trial (NCT02970318) of acalabrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL), and the potential impact of the results on clinical practice. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.